Exploring dysregulated immune response genes and endothelial dysfunction biomarkers as predictors of severe COVID-19.

Publication date: Jul 05, 2023

Identifying individuals and factors associated with severe cases of COVID-19 is crucial as the pandemic continues to spread globally. Effective biomarkers for predicting severe cases are essential for optimizing clinical management, therapy, and preventing unfavorable outcomes. This exploratory observational study aimed to investigate the expression of dysregulated immune response genes (ARG1, NOS2, ITGA4, and SELPLG) in total leukocytes, plasmatic levels of P-selectin and PSGL-1, and their clinical associations in patients with mild and severe COVID-19. Data from 117 confirmed COVID-19 patients (severe = 58, mild = 59) were collected upon admission. Gene expression was measured using RT-qPCR, and plasma protein levels assessed with ELISA assay. The severe COVID-19 patient group had a higher median age of 62. 0 (p = 0. 0001), a higher proportion of black individuals (86. 2%, p

Concepts Keywords
Elisa COVID-19
Immunopharmacol Dysregulated leucocyte response
Severe Endothelial activation
Therapy P-selectin


Type Source Name
disease IDO immune response
disease MESH COVID-19
disease VO effective
disease IDO assay

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *